FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955447737> ?p ?o ?g. }

• W2955447737 endingPage "e16254" @default.
• W2955447737 startingPage "e16254" @default.
• W2955447737 abstract "The aim of this study was to obtain real-world, US, observational data on the effect of baseline resistance-associated substitutions (RASs) on achieving sustained virologic response (SVR) in hepatitis C (HCV) patients treated with direct-acting antiviral (DAA) regimens; the need for long-term follow-up in post-SVR patients.It is uncertain if the presence of RASs limits efficacy to DAAs. Once SVR is achieved, society guidelines recommend long-term surveillance for hepatocellular carcinoma in certain patients. Real-world data are limited on these topics.Adult patients treated with DAAs at community hepatitis clinics between January 2015 and April 2017 were included in this study. Baseline resistance testing was performed before treatment. Per guidelines, post-SVR long-term monitoring was required in patients with F3 to F4 fibrosis before treatment or with elevated ALT levels (>19 U/L females; >30 U/L males).A total of 875 chronic, mostly GT1a (60%) HCV patients were treated with an approved DAA regimen. Average baseline AST and ALT were 75 and 67 U/L, respectively, and 47% had F3 to F4 fibrosis at baseline. SVR was achieved in 863 (98.6%) patients despite a high presence of baseline RASs (61%). Long-term monitoring was required post-SVR in 539 patients (62%).In a real-life, US cohort of HCV-infected patients, nearly all patients achieved SVR with available DAA regimens regardless of baseline RASs. Approximately two-thirds of these patients required long-term follow-up, despite viral eradication." @default.
• W2955447737 created "2019-07-12" @default.
• W2955447737 creator A5022850560 @default.
• W2955447737 creator A5029899153 @default.
• W2955447737 creator A5038247507 @default.
• W2955447737 creator A5042613443 @default.
• W2955447737 creator A5044163553 @default.
• W2955447737 creator A5045664376 @default.
• W2955447737 creator A5046175181 @default.
• W2955447737 creator A5048284127 @default.
• W2955447737 creator A5049514220 @default.
• W2955447737 creator A5053199491 @default.
• W2955447737 creator A5053405300 @default.
• W2955447737 creator A5053482898 @default.
• W2955447737 creator A5055149017 @default.
• W2955447737 creator A5059837921 @default.
• W2955447737 creator A5068304141 @default.
• W2955447737 creator A5075322332 @default.
• W2955447737 creator A5088878000 @default.
• W2955447737 date "2019-06-01" @default.
• W2955447737 modified "2023-10-13" @default.
• W2955447737 title "Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance" @default.
• W2955447737 cites W1908153784 @default.
• W2955447737 cites W2011978083 @default.
• W2955447737 cites W2019523835 @default.
• W2955447737 cites W2030305684 @default.
• W2955447737 cites W2118542945 @default.
• W2955447737 cites W2320330796 @default.
• W2955447737 cites W2413213127 @default.
• W2955447737 cites W2415783139 @default.
• W2955447737 cites W2531545597 @default.
• W2955447737 cites W2589068086 @default.
• W2955447737 cites W2601657236 @default.
• W2955447737 cites W2789775952 @default.
• W2955447737 cites W2790339633 @default.
• W2955447737 cites W2795863480 @default.
• W2955447737 cites W2803317671 @default.
• W2955447737 cites W2884426912 @default.
• W2955447737 cites W2893133496 @default.
• W2955447737 cites W2982512504 @default.
• W2955447737 cites W2992772421 @default.
• W2955447737 doi "https://doi.org/10.1097/md.0000000000016254" @default.
• W2955447737 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6617322" @default.
• W2955447737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31261592" @default.
• W2955447737 hasPublicationYear "2019" @default.
• W2955447737 type Work @default.
• W2955447737 sameAs 2955447737 @default.
• W2955447737 citedByCount "11" @default.
• W2955447737 countsByYear W29554477372020 @default.
• W2955447737 countsByYear W29554477372021 @default.
• W2955447737 countsByYear W29554477372022 @default.
• W2955447737 countsByYear W29554477372023 @default.
• W2955447737 crossrefType "journal-article" @default.
• W2955447737 hasAuthorship W2955447737A5022850560 @default.
• W2955447737 hasAuthorship W2955447737A5029899153 @default.
• W2955447737 hasAuthorship W2955447737A5038247507 @default.
• W2955447737 hasAuthorship W2955447737A5042613443 @default.
• W2955447737 hasAuthorship W2955447737A5044163553 @default.
• W2955447737 hasAuthorship W2955447737A5045664376 @default.
• W2955447737 hasAuthorship W2955447737A5046175181 @default.
• W2955447737 hasAuthorship W2955447737A5048284127 @default.
• W2955447737 hasAuthorship W2955447737A5049514220 @default.
• W2955447737 hasAuthorship W2955447737A5053199491 @default.
• W2955447737 hasAuthorship W2955447737A5053405300 @default.
• W2955447737 hasAuthorship W2955447737A5053482898 @default.
• W2955447737 hasAuthorship W2955447737A5055149017 @default.
• W2955447737 hasAuthorship W2955447737A5059837921 @default.
• W2955447737 hasAuthorship W2955447737A5068304141 @default.
• W2955447737 hasAuthorship W2955447737A5075322332 @default.
• W2955447737 hasAuthorship W2955447737A5088878000 @default.
• W2955447737 hasBestOaLocation W29554477371 @default.
• W2955447737 hasConcept C111368507 @default.
• W2955447737 hasConcept C114851261 @default.
• W2955447737 hasConcept C121332964 @default.
• W2955447737 hasConcept C126322002 @default.
• W2955447737 hasConcept C12725497 @default.
• W2955447737 hasConcept C127313418 @default.
• W2955447737 hasConcept C159047783 @default.
• W2955447737 hasConcept C177713679 @default.
• W2955447737 hasConcept C23131810 @default.
• W2955447737 hasConcept C2776455275 @default.
• W2955447737 hasConcept C61797465 @default.
• W2955447737 hasConcept C62520636 @default.
• W2955447737 hasConcept C71924100 @default.
• W2955447737 hasConcept C86803240 @default.
• W2955447737 hasConcept C89423630 @default.
• W2955447737 hasConceptScore W2955447737C111368507 @default.
• W2955447737 hasConceptScore W2955447737C114851261 @default.
• W2955447737 hasConceptScore W2955447737C121332964 @default.
• W2955447737 hasConceptScore W2955447737C126322002 @default.
• W2955447737 hasConceptScore W2955447737C12725497 @default.
• W2955447737 hasConceptScore W2955447737C127313418 @default.
• W2955447737 hasConceptScore W2955447737C159047783 @default.
• W2955447737 hasConceptScore W2955447737C177713679 @default.
• W2955447737 hasConceptScore W2955447737C23131810 @default.
• W2955447737 hasConceptScore W2955447737C2776455275 @default.
• W2955447737 hasConceptScore W2955447737C61797465 @default.
• W2955447737 hasConceptScore W2955447737C62520636 @default.

• next